Sign In
Buy INO
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
Why Inovio Stock Tumbled on a Good Day for the Market Wednesday
09:12pm, Wednesday, 02'nd Mar 2022 The Motley Fool
The company's Q4 results didn't provide a lot of fuel for optimism.
Why Inovio Stock Tumbled on a Good Day for the Market Wednesday
04:12pm, Wednesday, 02'nd Mar 2022
The company's Q4 results didn't provide a lot of fuel for optimism.
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
12:50pm, Wednesday, 02'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome
Inovio COVID vaccine weaker vs Omicron in lab test; phase 3 trial enrollment paused
09:56am, Wednesday, 02'nd Mar 2022 Seeking Alpha
Inovio Pharmaceuticals (INO) is pausing enrollment in a phase 3 trial of its COVID-19 vaccine INO-4800 to amend the main goal of the study after the shot showed significantly…
Inovio Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
08:57am, Wednesday, 02'nd Mar 2022 Seeking Alpha
Inovio Pharmaceuticals (INO) Q4 2021 Earnings Call Transcript
03:30am, Wednesday, 02'nd Mar 2022 The Motley Fool
INO earnings call for the period ending December 31, 2021.
Inovio Pharmaceuticals (INO) Q4 2021 Earnings Call Transcript
03:30am, Wednesday, 02'nd Mar 2022 The Motley Fool
INO earnings call for the period ending December 31, 2021.
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
02:19am, Wednesday, 02'nd Mar 2022 Seeking Alpha
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates
11:05pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals results miss on the bottom line; shares down 9% (INO)
09:42pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Inovio Pharmaceuticals'' (INO) Q4 2021 results missed on the bottom line as its net loss significantly widened.
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
09:19pm, Tuesday, 01'st Mar 2022
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
Inovio Pharmaceuticals GAAP EPS of -$1.45 misses by $0.19, revenue of $1.77M beats by $0.31M
09:11pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Inovio Pharmaceuticals press release (INO): FY GAAP EPS of -$1.45 misses by $0.19.Revenue of $1.77M (-76.1% Y/Y) beats by $0.31M.Shares -5.56%.As of December 31, 2021, cash and…
2 Money-Burning Biotech Stocks to Avoid
01:45pm, Tuesday, 01'st Mar 2022 The Motley Fool
These companies have taken a beating, and there's no relief on the horizon.
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
12:51pm, Tuesday, 01'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Editas Gains On Resolution Of CRISPR Gene Editing Patent Case
Editas Medicine, Inc. (NASDAQ: EDIT) sai
Can Inovio Pharmaceuticals Q4 results bring earnings surprise?
05:20pm, Monday, 28'th Feb 2022 Seeking Alpha
Inovio Pharmaceuticals (NASDAQ:INO) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$0.32 (-128.6% Y/Y) and…
